1.
Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1480-91. doi: 10.1111/jdv.12323. Epub 2013 Nov 28.
PMID: 24283696.
2.
Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995 Nov;133(5):699-703. doi: 10.1111/j.1365-2133.1995.tb02741.x.PMID: 8555019.
3.
Cozzani E, Agnoletti AF, Speziari S, Schiavetti I, Zotti M, Persi A, Drago F, Parodi A. Epidemiological study of
onychomycosis in older adults with onychodystrophy. Geriatr Gerontol Int. 2016 Apr;16(4):486-91. doi: 10.1111/ggi.12496. Epub 2015 May 15. PMID: 25981058.
4. Leung AKC, Lam JM, Leong KF, Hon KL, Barankin B, Leung AAM, Wong AHC. Onychomycosis: An Updated Review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):32-45. doi: 10.2174/1872213X13666191026090713. PMID: 31738146; PMCID: PMC7509699.
5. Maskan Bermudez N, Rodríguez-Tamez G, Perez S, Tosti A. Onychomycosis: Old and New. J Fungi
(Basel). 2023 May 12;9(5):559. doi: 10.3390/jof9050559. PMID: 37233270; PMCID: PMC10219498
6. Nenoff P, Reinel D, Mayser P, et al. S1 guideline onychomycosis. JDDG: Journal der Deutschen
Dermatologischen Gesellschaft. 2023; 21: 678–692. doi: 10.1111/ddg.14988.
7 Loprox cream in:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018748s024,019824s023,020519s016lbl.pdf
8. Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853-867. doi:10.1016/j.jaad.2018.05.1260
9. Maggioni D, Cimicata A, Praticò A, et al. Clinical Evaluation of a Topical Formulation for the Management of Onychomycosis. J Clin Aesthet Dermatol. 2020;13(7):53-57. PMID: 32983339. PMCID: PMC7492023.
10. Piraccini BM, Starace M, Rubin AI, et al. Onychomycosis: Recommendations for Diagnosis, Assessment of Treatment Efficacy, and Specialist Referral. The CONSONANCE Consensus Project. Dermatol Ther (Heidelb). 2022;12(4):885-898. doi:10.1007/s13555-022-00698-x
11. Piraccini BM, Iorizzo M, Lencastre A, Nenoff P, Rigopoulos D. Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis. Dermatol Ther (Heidelb). 2020 Oct;10(5):917-929. doi: 10.1007/s13555-020-00420-9. Epub 2020 Jul 23. PMID: 32705532; PMCID: PMC7477053.
12. Ricardo JW, Lipner SR. Safety of current therapies for onychomycosis. Expert Opin Drug Saf. 2020;19(11):1395-1408. doi:10.1080/14740338.2020.1829592.
13. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4 Suppl):S70-S80. doi:10.1067/mjd.2000.109071.
14. Piraccini BM, Starace M, Toft A. Early Visible Improvements during K101-03 Treatment: An
Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis. Dermatology. 2017;233(2-3):178-183. doi:10.1159/000478257
15. Naeimifar A, Samadi A, Ahmad Nasrollahi S, et al. Efinaconazole topical solution 10%: Formulation and
efficacy assessment in the treatment of toenail onychomycosis. Mycoses. 2020;63(5):517-524. doi:10.1111/myc.13062.
16. Arenas R. Las onicomicosis. Aspectos clínico-epidemiológicos, micológicos y terapéuticos
[Onychomycosis. Clinico-epidemiological mycological and therapeutic aspects]. Gac Med Mex. 1990;126(2):84-91. PMID: 2143740
17. Yadav P, Singal A, Pandhi D, Das S. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial. Indian J Dermatol Venereol Leprol. 2015;81(4):363-369. doi:10.4103/0378-6323.158634.
18. Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150 mg
formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022;33(4):2085-2093. doi:10.1080/09546634.2021.1914812.
19. Carney C, Tosti A, Daniel R, Scher R, Rich P, DeCoster J, Elewski B. A new classification system
for grading the severity of onychomycosis: Onychomycosis Severity Index. Arch Dermatol. 2011 Nov;147(11):1277-82. doi: 10.1001/archdermatol.2011.267. PMID: 22106113.
20. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of
toenail onychomycosis. J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S70-80. doi: 10.1067/mjd.2000.109071. PMID: 11051136.
21. Shemer A, Nathansohn N, Trau H, Amichai B, Grunwald MH. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. J Dermatol. 2010 Feb;37(2):137-9. doi: 10.1111/j.1346-8138.2009.00773.x. PMID: 20175847.